Last Updated: May 1, 2026

CLINICAL TRIALS PROFILE FOR ESOMEPRAZOLE SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Esomeprazole Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00428701 ↗ An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium Completed AstraZeneca Phase 4 2006-10-01 This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.
NCT00464308 ↗ A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed Janssen-Cilag Pty Ltd Phase 4 2006-11-01 The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.
NCT01471925 ↗ Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC Withdrawn Eurofarma Laboratorios S.A. Phase 3 1969-12-31 A phase III, randomized, open-label, superiority study comparing the incremental product esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the treatment of gastroesophageal reflux disease. The study will enroll 94 patients in each arm (total of 188 patients).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Esomeprazole Sodium

Condition Name

Condition Name for Esomeprazole Sodium
Intervention Trials
Gastroesophageal Reflux Disease 2
Healthy Subjects 2
Healthy Volunteers 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Esomeprazole Sodium
Intervention Trials
Gastroesophageal Reflux 3
Esophagitis, Peptic 2
Dyssomnias 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Esomeprazole Sodium

Trials by Country

Trials by Country for Esomeprazole Sodium
Location Trials
Brazil 6
United States 5
China 2
Australia 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Esomeprazole Sodium
Location Trials
Missouri 1
Tennessee 1
Pennsylvania 1
Louisiana 1
Delaware 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Esomeprazole Sodium

Clinical Trial Phase

Clinical Trial Phase for Esomeprazole Sodium
Clinical Trial Phase Trials
PHASE1 2
Phase 4 4
Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Esomeprazole Sodium
Clinical Trial Phase Trials
Completed 6
NOT_YET_RECRUITING 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Esomeprazole Sodium

Sponsor Name

Sponsor Name for Esomeprazole Sodium
Sponsor Trials
Bio-innova Co., Ltd 2
Fundação de Amparo à Pesquisa do Estado de São Paulo 1
Federal University of São Paulo 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Esomeprazole Sodium
Sponsor Trials
Industry 8
Other 4
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

ESOMEPRAZOLE SODIUM: Clinical-Trials Update, Market Analysis, and Projection

Last updated: April 23, 2026

What is esomeprazole sodium in the market?

Esomeprazole sodium is the S-enantiomer proton pump inhibitor (PPI) used for acid-related gastrointestinal indications. Commercial positioning is largely driven by: (i) broad-label coverage (GERD and related erosive disease), (ii) extensive formulary penetration via branded-to-generic transition in many markets, and (iii) long-standing reimbursement and physician familiarity.

Core commercial characteristics

  • Mechanism class: Proton pump inhibitor (acid suppression)
  • Indication set (high-level): GERD, erosive esophagitis, maintenance therapy, symptomatic GERD; additional label areas vary by jurisdiction and product line
  • Competitive landscape: Multi-generic class with some originator and line-extended brands historically; post-patent markets are dominated by generics and authorized generics

What clinical-trials activity exists for esomeprazole sodium now?

Esomeprazole sodium’s clinical development in 2026 is dominated by non-pivoting studies rather than first-in-class trials. Typical activity in this molecule class includes:

  • Bioequivalence and formulation work for generics, authorized generics, and line extensions
  • Pharmacokinetic (PK) and safety bridging studies across age groups, comorbidities, and special populations
  • Real-world and observational studies related to adherence, persistence, and switching across PPIs

Clinical trials update (what to expect in current registries):

  • Trial volume is generally steady but concentrated in:
    • Bioequivalence studies (oral solid dose)
    • Switching and regimen studies (conversion between oral and delayed-release formats where applicable)
    • Pediatric or elderly bridging where label maintenance requires periodic evidence

Signal for business relevance: The molecule’s evidence base is mature; new clinical “value” typically comes from next-generation formulations, fixed-dose combinations, or regulatory strategy rather than new clinical endpoints that change practice.

How is the market structured and who competes with esomeprazole sodium?

Esomeprazole sodium competes in a class market with PPIs that include omeprazole, pantoprazole, lansoprazole, rabeprazole, and other esomeprazole salt variants. Market dynamics differ by geography based on:

  • Patent and exclusivity expiration
  • Generic penetration speed
  • Tender pricing and channel contracting
  • Reimbursement rules and step-therapy

Competitive buckets

Segment Typical product profile What drives share
Generic esomeprazole sodium Low-cost oral PPI, often multiple strengths and pack sizes Unit price, availability, tenders
Other generics in the PPI class Omeprazole/pantoprazole/lansoprazole competitors Physician preference, formulary positioning
Branded/authorized branded variants Historically originator or authorized line extensions Marketing history, retention in specific formularies, limited competition in some regions

What is the demand base?

Demand is anchored by chronic and recurrent indications:

  • GERD prevalence and persistence of symptoms drive repeat therapy
  • Long-term use patterns exist, though treatment duration is influenced by guideline adherence and step-down strategies
  • Switching within the class remains common due to price and formulary controls

Key demand characteristics

  • High baseline prevalence: Acid reflux and related symptoms create a large addressable population
  • Class substitution: PPIs are frequently interchangeable clinically; this pressures pricing in mature markets
  • Formulary control: Many health systems apply PPIs as interchangeable options in therapeutic classes, enabling rapid generic substitution

What do price and volume trends imply for revenue?

For established PPIs, value growth is constrained by generics and tender contracting. Revenue growth typically comes from one of these routes:

  • Volume growth from population and persistence
  • Mix improvement (pack size, higher strength, preferred formulation)
  • Market-specific pricing structures where generics enter slower or authorized branded products retain share longer

In mature markets, unit price erosion usually outpaces volume growth. In emerging markets, uptake can track healthcare access expansion but still faces aggressive pricing once generics scale.

Market projection: How should esomeprazole sodium perform by 2030?

Because esomeprazole sodium is an established molecule with broad generic availability in many jurisdictions, projection should be read through class dynamics: pricing pressure, tendering, and generic substitution.

Projection framework (practical business view)

  • Upside levers
    • Growth in healthcare access in emerging markets
    • Persistence in GERD treatment regimens
    • Strength and format mix that favors higher ASP segments (where reimbursement supports it)
  • Downside levers
    • Faster generic penetration
    • Strongest-price tender outcomes
    • Payer step-therapy protocols that prefer the lowest-cost PPI in the formulary

Scenario view (global, directionally)

Scenario Assumptions Revenue trajectory vs. current
Base case Gradual volume growth offset by continuing ASP decline Flat to modest growth in currency terms; weaker growth in real terms
Upside Slower price erosion in select regions and better mix Low single-digit growth possible through mix
Downside Aggressive tendering and rapid generic substitution Decline in revenue despite stable volumes

Actionable read-through: For investors or R&D sponsors, the molecule’s standalone commercial ceiling is typically class-limited. The highest-return opportunities usually sit in:

  • New formulations that improve bioavailability, stability, or dosing convenience
  • Regulatory-driven differentiation (pediatric, specific populations, or particular dosage forms where evidence is needed)
  • Combination products or new delivery systems that reduce GERD burden or improve adherence

What is the patent and exclusivity landscape impact?

For mature small-molecule PPIs, patent-based supply restriction is usually limited to:

  • Local secondary patents (formulation, method, polymorph, process) that vary by region and may have narrow scope
  • Data exclusivity and line-extension protections that are time-bounded and jurisdiction-dependent
  • Transition to generics once primary rights expire

Business implication: market share and pricing typically follow generic entry curves more than clinical novelty.

Competitive strategy implications

If you are a generic or authorized generic sponsor

  • Win tenders with price competitiveness and reliable supply
  • Invest in bioequivalence strength and manufacturing robustness
  • Use pack-size and strength portfolio optimization to capture formulary slots

If you are an originator line extension or partner

  • Target gaps in the formulary where authorized-branded or niche indications maintain friction against substitution
  • Pursue differentiation through formulation where it improves patient adherence or dosing convenience
  • Align with guideline changes that shift usage patterns (step-down and duration management)

Key metrics to track for management and underwriting

For ongoing updates and projection refinement, monitor:

  • Tender price indices by major procurement regions
  • Formulary placement and switching rates among PPIs
  • Generic market share changes after new entrants
  • Regulatory actions around manufacturing compliance and product approvals
  • Prescription volume trends in GERD and erosive esophagitis cohorts

Key Takeaways

  • Esomeprazole sodium is a mature PPI with clinical activity dominated by bioequivalence, formulation, and bridging studies rather than practice-changing efficacy trials.
  • Market performance is constrained by generic competition and payer substitution across the PPI class, with value growth usually limited to volume and mix rather than pricing.
  • 2030 outcomes are most plausibly flat to modestly positive in currency terms under base-case assumptions, with revenue sensitive to tender outcomes and regional generic entry speed.
  • The most investable pathways are formulation and regulatory differentiation, targeted populations, and supply and tender execution, not new primary clinical development.

FAQs

  1. Is esomeprazole sodium still seeing meaningful Phase 3 efficacy trials?
    Clinical activity is typically concentrated in bioequivalence, formulation, and bridging rather than new Phase 3 efficacy pivots.

  2. What is the main driver of revenue for esomeprazole sodium in generic-heavy markets?
    Pricing (tender outcomes) and mix (strength and pack utilization) usually dominate over incremental clinical differentiation.

  3. How does switching behavior affect market projection?
    PPIs are often treated as interchangeable within formularies, so switching accelerates generic take-up and puts downward pressure on ASP.

  4. Which regions typically offer better upside for established PPIs?
    Regions with slower generic penetration, expanding healthcare access, or persistent friction against substitution can show better revenue resilience.

  5. What product levers most improve commercial outcomes?
    Reliable supply, price competitiveness for tenders, and formulation or packaging changes that improve adherence and reimbursement fit.

References

[1] National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] World Health Organization. ATC classification system. https://www.whocc.no/atc/
[4] U.S. National Library of Medicine. PubChem Compound Summary for Esomeprazole. https://pubchem.ncbi.nlm.nih.gov/
[5] EMA. European public assessment reports and product information for proton pump inhibitors. https://www.ema.europa.eu/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.